Healthcare [ 2/11 ] | Drug Manufacturers—Specialty & Generic [ 24/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 3, 22 | -0.27
Decreased by
-124.77%
|
-0.44
Increased by
+38.64%
|
Aug 4, 22 | -0.32
Increased by
+55.56%
|
-0.56
Increased by
+42.86%
|
May 5, 22 | -0.66
Increased by
+1.49%
|
-0.65
Decreased by
-1.54%
|
Feb 24, 22 | 1.09
Increased by
+251.39%
|
-0.67
Increased by
+262.69%
|
Feb 23, 22 | 1.09
Increased by
+237.97%
|
-0.67
Increased by
+262.69%
|
Nov 4, 21 | -0.72
Decreased by
-10.77%
|
-0.62
Decreased by
-16.13%
|
Aug 4, 21 | -0.67
Increased by
+19.28%
|
-0.64
Decreased by
-4.69%
|
May 5, 21 | -0.72
Increased by
+13.25%
|
-0.68
Decreased by
-5.88%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 36.13 M
Increased by
+23.25%
|
-26.83 M
Increased by
+32.41%
|
Decreased by
-74.25%
Increased by
+45.16%
|
Jun 30, 22 | 33.31 M
Increased by
+22.53%
|
-19.37 M
Increased by
+49.93%
|
Decreased by
-58.15%
Increased by
+59.14%
|
Mar 31, 22 | 29.84 M
Increased by
+29.89%
|
-35.89 M
Increased by
+14.47%
|
Decreased by
-120.30%
Increased by
+34.15%
|
Dec 31, 21 | 114.67 M
Increased by
+364.55%
|
45.53 M
Increased by
+198.69%
|
Increased by
+39.71%
Increased by
+121.24%
|
Sep 30, 21 | 29.31 M
Increased by
+45.97%
|
-39.69 M
Decreased by
-0.11%
|
Decreased by
-135.40%
Increased by
+31.42%
|
Jun 30, 21 | 27.18 M
Increased by
+50.75%
|
-38.69 M
Increased by
+19.71%
|
Decreased by
-142.31%
Increased by
+46.74%
|
Mar 31, 21 | 22.97 M
Increased by
+12.92%
|
-41.96 M
Increased by
+14.58%
|
Decreased by
-182.69%
Increased by
+24.36%
|
Dec 31, 20 | 24.68 M
Increased by
+0.11%
|
-46.14 M
Increased by
+16.21%
|
Decreased by
-186.92%
Increased by
+16.30%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.